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to consider patient treatment history when interpreting cur-
rently used genotypic antiretroviral resistance tests.
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Abstract
In the present study, we retrospectively studied clinical and labo-
ratory ﬁndings associated with cytomegalovirus (CMV) infection
in immunocompetent patients. We focused on severe CMV infec-
tion. Among 38 patients, ﬁve had a severe form of infection: one
had meningitis, one had symptomatic thrombocytopenia and three
had venous thromboses with pulmonary embolism, a rarely
described complication. CMV-induced thrombosis has been
reported in immunocompromised patients such as transplant
recipients and patients with AIDS. Recent case reports have also
described thrombotic phenomena in immunocompetent patients
with CMV infection. Our study suggests that venous thrombosis
during acute CMV infection is an underestimated complication.
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Acute cytomegalovirus (CMV) infection in immunocompetent
patients is common worldwide, with seroprevalence rates
ranging from 40% to 100%, depending on country, socio-eco-
nomic conditions and age [1,2]. In immunocompetent adults,
CMV infection is most often asymptomatic. In about 10%, a
subclinical, mononucleosis-like syndrome occurs, character-
ized by malaise, fever, mild liver function abnormalities and
lymphocytosis with atypical lymphocytes. Illness in these
cases is usually mild and self-limiting [3].
More rarely, acute CMV infection is revealed by prolonged
fever, cervical lymphadenitis and arthralgia. Multiple organ
involvement can also occur. The gastrointestinal tract (colitis)
and the central nervous system (meningitis, encephalitis and
transverse myelitis) are the most frequent sites of severe
CMV infection, but other manifestations can be observed,
such as haematological disorders (haemolytic anaemia and
thrombocytopenia), thrombosis of the venous or arterial vas-
cular system, ocular involvement and lung disease [4].
We decided to conduct a retrospective study in immuno-
competent patients with evidence of CMV infection, with the
objective of describing the symptoms and abnormal labora-
tory ﬁndings, and to assess the proportion of severe cases of
CMV infection. In this study, we selected and reviewed all
records of outpatients or hospitalized patients in the infec-
tious and tropical diseases department at Angers Hospital,
from 1 January 1995 to 31 December 2006, who were coded
in the PMSI system (hospital medical informatic systems, used
throughout France) with ‘cytomegalovirus’ as the principal or
an associated diagnosis. Our exclusion criteria were age
under 16 years, pregnancy and immunocompromised status.
Conﬁrmed acute CMV infection was deﬁned as infection
with CMV IgM and/or IgG seroconversion (by ELISA) and/or
a four-fold increase in CMV IgG titre between two samples
collected at least 2 weeks apart and/or PP65-positive
antigenaemia (by immunoﬂuorescence) and/or CMV-positive
viraemia. Probable acute CMV infection was deﬁned as
infection in the presence of CMV IgM with epidemiological
features strongly suggestive of a ﬂu-like syndrome and/or a
mononucleosis syndrome and/or altered liver function. A
mononucleosis syndrome was deﬁned as more than 50% of
lymphocytes with a large, hyperbasophilic form.
We deﬁned as severe any CMV infection for which the
patient was hospitalized with organ involvement, i.e. of the
gastrointestinal tract, central nervous system, lungs, eyes or
skin, and with haematological disorders. In addition, any
CMV infection causing vascular thrombosis was included.
We retrieved information from the records demographic
(age and sex), clinical (cause of hospitalization, medical his-
tory and initial general and organ-speciﬁc symptoms), labora-
tory and other work-up (chest radiography and biopsies)
ﬁndings. Finally, we recorded the treatment and the disease
course for each patient.
TABLE 1. Clinical and laboratory
ﬁndings associated with cytomega-
lovirus infection
Horwitz
[8],
n = 82,
1986
Ragnaud
[9],
n = 34,
1994
Faucher
[10],
n = 116,
1998
Bonnet
[11],
n = 115,
2001
Wreghitt
[3],
n = 124,
2003
Present
study,
n = 38
Clinical symptoms (%)
Fever 93.5 100 99 94.8 46 92.1
Duration of fever (days) – 25 21.5 25 18
Asthenia – – 72.4 73 – 68.4
Headache 8.5 53 54 51.3 14 50
Sweats – 50 35.4 42 46 23.7
Chills – 21 38.8 32.2 – 39.5
Myalgia 15.8 53 45.6 31.3 36 42.1
Arthralgia – 15 12 23.5 17 15.8
Cough – 15 26.3 20 – 23.7
Diarrhoea 2.4 21 6.3 10.4 5 15.8
Abdominal pain 9.7 21 17.4 26 4 10.5
Weight loss – 21 4.9 35.6 2 7.9
Nausea, vomiting – – – 10.4 – 10.5
Maculopapular rash 7.3 21 6.1 20 2 10.5
Hepatomegaly – 9 11.4 25 – 10.5
Splenomegaly 26.8 24 35.7 23.5 3 15.8
Lymphadenopathy 17.1 15 21.2 19.1 24 18.4
Pharyngeal pain 30.9 – 13.1 9.6 – 7.9
Abnormal laboratory
ﬁndings (%)
Anaemia 67.4 8.8 21.4 20 – 15.8
Thrombocytopenia 12.5 2.9 1.8 25 3 28.9
Lymphocytosis with
atypical lymphocytes
100 91 94.6 64 – 39.5
Hepatitic cytolysis 94.8 97 87.8 90 – 91.9
852 Clinical Microbiology and Infection, Volume 16 Number 7, July 2010 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 848–854
During the study period, 70 patients were reviewed and
38 fulﬁlled the inclusion criteria. The mean patient age was
45 ± 16 years (range, 23–80 years). The ratio of male to
female patients was 1 : 2.2.
Patients were seen mainly because they sought medical
advice or were hospitalized for fever of unknown origin,
hepatitis, weight loss, haematological disorders. The most
typical symptoms associated with CMV infection in these
immunocompetent patients are shown in Table 1 and are
compared with those reported in other studies. Fever was
noted in 92% of patients, with a mean duration of 18 days.
In these cases, asthenia, headache and chills were the main
clinical symptoms. Abnormal laboratory ﬁndings were mainly
hepatic cytolysis (in 92%) and thrombocytopenia (in 29%). A
mononucleosis syndrome was found in only 40% of patients.
The average length of hospitalization was 7 ± 7 days (range,
2–35 days). All patients recovered completely, but we identi-
ﬁed ﬁve patients (13.2%) with severe CMV infection. The
ﬁrst one had a central nervous system disorder with menin-
gitis. He did not receive any speciﬁc antiviral therapy and
remained well after a hospitalization period of 7 days. The
second patient had severe symptomatic thrombocytopenia
requiring treatment with corticosteroids; he recovered com-
pletely. The three remaining patients (7.9%) had vascular
thrombosis with pulmonary embolism. A 38-year-old white
woman had CMV-associated acute ulcerative colitis. CMV
inclusion antibodies were found in rectal and colic biopsy
samples, and CMV inclusions were conﬁrmed by immuno-
ﬂuorescence. A few days after hospitalization, the patient
had a thrombosis of the right iliac vein with bilateral pulmo-
nary embolism of moderate severity, conﬁrmed by ventila-
tion–perfusion scintigraphy. A coagulation screen revealed
no pathological values. In addition to intravenous heparin
treatment, anti-CMV therapy with intravenous ganciclovir
was started. The patient recovered in 1 week. The second
case was that of a 32-year-old white woman with a typical
CMV infection with prolonged fever who became asymptom-
atic 20 days after the ﬁrst symptoms. Subsequently, 4 days
after hospitalization, she had fever again. Doppler ultrasound
revealed a left internal jugular vein thrombosis associated
with a pulmonary embolism of moderate severity in the left
chest. After initial treatment with low molecular weight hep-
arin, and then with oral anticoagulants, the patient recov-
ered. A factor V Leiden heterozygous mutation was found.
These two cases have previously been reported in detail [5].
The third case was that of an 82-year-old white woman, also
with evidence of recent CMV infection, who quickly recov-
ered after several days of hospitalization. Two weeks later,
she was hospitalized again for persistent fever (38C) and
dyspnoea that worsened gradually over several days. A bilat-
eral pulmonary embolism of moderate severity was con-
ﬁrmed. A coagulation screen revealed no pathological values.
She recovered completely after anticoagulant treatment for
6 months. In these three cases, the diagnosis of acute CMV
infection, as deﬁned above, was conﬁrmed.
CMV can cause severe disease in immunocompro-
mised patients. Clinical symptoms are well described and can
be observed especially in patients with AIDS or after
transplantation following high-dose immunosuppressive ther-
apy [6,7]. On the other hand, there are only several reports
describing symptoms of CMV infection in immunocompetent
patients, because in this case infection is considered to have a
benign, self-limiting course. However, a considerable number
of case reports describing severe clinical manifestations can
be found. A recent review retrieved articles reporting such
cases [4]. The authors found 290 immunocompetent patients
with severe CMV infection. Colitis (91 patients) and central
nervous system problems (56 patients) were the most fre-
quent manifestations of severe CMV infection. Haematologi-
cal disorders (35 patients) with haemolytic anaemia and
thrombocytopenia, ocular involment (16 patients) and lung in-
volment (nine patients) were also described. They also found
19 cases, from all over the world, of venous thrombosis with
various types of blood vessel thrombosis and pulmonary
embolism, which is described as a very rare manifestation of
severe CMV infection.
Concerning the frequency of symptoms and abnormal lab-
oratory ﬁndings in cases of severe CMV infection, our results
do not differ from those of other studies, except for mono-
nucleosis syndrome, which was found more rarely [4,8–11].
More surprising were the frequencies and types of severe
CMV infection associated with venous thrombosis, which
was seen in three cases (7.9%). These cases were diagnosed
not during initial hospitalization but long after the onset of
symptoms and after patient discharge. No comprehensive
interpretation of this association is yet available. Venous
thrombosis could be explained by hospitalization itself in
patients who are bedridden and suffer from severe infection,
but, in the literature, data strongly support a causal relation-
ship, owing to the intrinsic procoagulant properties of CMV.
Several mechanisms have been proposed for the role of
CMV-induced vascular thrombosis. The virus can directly
invade endothelial cells, causing vascular endothelium damage
that activates coagulation factors. Another explanation is that
CMV can enhance coagulant properties by increasing throm-
bin production and decreasing the production of prostaglan-
din and interleukin-2, both of which support platelet
adhesion [12].
It has also been suggested that one of the immediate-early
gene products of CMV, namely IE84, binds to P53 and
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inhibits the transcriptional activity of its gene, thus inhibiting
P53-mediated apoptosis and enhancing smooth muscle cell
proliferation, which is a crucial event in the development of
atherosclerosis and restenosis [13]. Finally, CMV may also
induce the production of antiphospholipid antibodies [14,15].
In conclusion, our study suggests that thrombosis in
immunocompetent patients with CMV infection may not be
as rare as previously thought. This complication is some-
times discovered only several weeks after the initial diagno-
sis of CMV infection. This is, to our knowledge, the ﬁrst
study to show a large percentage of venous thromboses
among a population of immunocompetent patients with
acute CMV infection. As it has been performed in a single
centre, it must be conﬁrmed by larger studies.
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